Related references
Note: Only part of the references are listed.Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis
R. H. Dahlrot et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2018)
Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression
Fengming Lan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment
Jun-Hai Tang et al.
EXPERIMENTAL CELL RESEARCH (2016)
FM19G11 reverses endothelial dysfunction in rat and human arteries through stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α activation
M. El Assar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Dose-dense Temozolomide: Is It Still Promising?
Motoo Nagane
NEUROLOGIA MEDICO-CHIRURGICA (2015)
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance
Malin Wickstrom et al.
NATURE COMMUNICATIONS (2015)
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma
Marta Penas-Prado et al.
NEURO-ONCOLOGY (2015)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Towards personalized therapy for patients with glioblastoma
Katsuyuki Shirai et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
K. A. van Nifterik et al.
BRITISH JOURNAL OF CANCER (2010)
FM19G11 A new modulator of hif that links mTOR activation with the DNA damage checkpoint pathways
Francisco Javier Rodriguez-Jimenez et al.
CELL CYCLE (2010)
FM19G11, a New Hypoxia-inducible Factor (HIF) Modulator, Affects Stem Cell Differentiation Status
Victoria Moreno-Manzano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide
Gentian Kaloshi et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
Jennifer A. Quinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
